{"Clinical Trial ID": "NCT00445458", "Intervention": ["INTERVENTION 1:", "Neratinib 160 mg + Paclitaxel 80 mg/m2", "Neratinib 160 mg qd + Paclitaxel 80 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle.", "INTERVENTION 2:", "Neratinib 240 mg + Paclitaxel 80 mg/m2", "Neratinib 240 mg qd + Paclitaxel 80 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle."], "Eligibility": ["Incorporation criteria:", "Incorporation criteria for both parts of the clinical trial:", "Good performance", "Normal ejection fraction", "Adequate cardiac, renal and hepatic function", "A proper blood count", "At least one measurable target injury", "Negative pregnancy test for women", "\u2022 Inclusion criteria for the first part only:", "- Solid tumour confirmed pathologically uncurable with standard treatment available", "\u2022 Inclusion criteria for the second part only:", "- Pathologically confirmed breast cancer", "HER2 positive tumor", "Previous treatment with Herceptin", "- Exclusion criteria:", "- Exclusion criteria for both parts of the clinical trial:", "Major surgery, radiotherapy, chemotherapy or research agents within two weeks of treatment 1", "Subjects presenting a bone or skin as the only disease site", "Metastasis of the active central nervous system", "A significant heart disease or dysfunction", "Important gastrointestinal disorders", "Inability or unwillingness to swallow HKI-272 capsules", "A prior exposure to HKI-272 or other HER2-targeted agents, with the exception of trastuzumab (part 2 only).", "Treatment with a taxane within 3 months of treatment 1 day", "Power or sensory neuropathy of grade 2 or higher", "Pregnant or lactating women", "Hypersensitivity to paclitaxel or cremophor EL", "Prior treatment with anthracyclines at a cumulative dose of > 400 mg/m^2", "Any other cancer within 5 years, with the exception of contralateral breast cancer, properly treated cervical carcinoma in situ or properly treated basal or squamous skin carcinoma", "- Exclusion criteria for Part II only:", "More than one (arm A) or three (arm B) prior cytotoxic chemotherapy for metastatic disease"], "Results": ["Performance measures:", "Dose limiting toxicity Incidence of Neratinib in combination with paclitaxel", "In subjects with neratinib-treated solid tumours administered daily in combination with paclitaxel 80 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle.", "Duration: from first dose to day 28", "Results 1:", "Dose/group title: Neratinib 160 mg + Paclitaxel 80 mg/m", "Description of the arm/group: Neratinib 160 mg qd + Paclitaxel 80 mg/m IV on days 1, 8 and 15 of a 28-day cycle.", "Total number of participants analysed: 3", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%", "Results 2:", "Dose/group title: Neratinib 240 mg + Paclitaxel 80 mg/m", "Description of the arm/group: Neratinib 240 mg qd + Paclitaxel 80 mg/m IV on days 1, 8 and 15 of a 28-day cycle.", "Total number of participants analysed: 5", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/3 (33.33 per cent)", "Anemia 0/3 (0.00 %)", "Febrile neutropenia 0/3 (0.00 %)", "- Leucopenia 0/3 (0.00 %)", "Sinus tachycardia 1/3 (33.33%)", "Category 0/3 (0.00 %)", "Abdominal disorders 1/3 (33.33%)", "Diarrhoea 1/3 (33.33%)", "- Nausea 0/3 (0.00 %)", "Vomiting 0/3 (0.00 %)", "- Fatigue 0/3 (0.00 %)", "Gas disturbance 0/3 (0.00 %)", "Peripheral edema 0/3 (0.00 %)", "Pyrexia 0/3 (0.00 %)", "Adverse Events 2:", "Total: 4/5 (80.00 per cent)", "Anemia 2/5 (40.00 %)", "Febrile neutropenia 0/5 (0.00 %)", "- Leucopenia 0/5 (0.00 %)", "Sinus tachycardia 0/5 (0.00 %)", "Category 0/5 (0.00 %)", "Abdominal disorders 0/5 (0.00 %)", "Diarrhoea 1/5 (20.00%)", "Nausea 1/5 (20.00 %)", "Vomiting 1/5 (20.00 %)", "- Fatigue 0/5 (0.00 %)", "Gas disturbance 0/5 (0.00 %)", "Peripheral edema 0/5 (0.00 %)", "Pyrexia 1/5 (20.00 %)"]}